| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharmaceutical
|
Oct 21, 2026 | BUY |
Strong Buy
+63.6% avg upside
52 analysts
|
$90.00
53.87% Upside
|
+6.0% | Β· |
|
ABVX
Abivax SA Sponsored ADR
|
Oct 21, 2026 | BUY |
Strong Buy
+54.7% avg upside
16 analysts
|
$175.00
102.01% Upside
|
-12.2% | Β· |
|
SRRK
Scholar Rock Holding
|
Oct 21, 2026 | BUY |
Strong Buy
+48.3% avg upside
23 analysts
|
$75.00
70.79% Upside
|
+4.8% | Β· |
|
ARGX
Argenx Se
|
Oct 21, 2026 | BUY |
Strong Buy
-8.2% avg upside
48 analysts
|
$1215.00
36.03% Upside
|
+6.5% | Β· |
|
ARDX
Ardelyx
|
Oct 21, 2026 | BUY |
Strong Buy
+324.2% avg upside
21 analysts
|
$15.00
395.00% Upside
|
+1.6% | Β· |
|
AKBA
Akebia Therapeutics
|
Oct 21, 2026 | BUY |
Strong Buy
+1184.8% avg upside
16 analysts
|
$4.00
466.17% Upside
|
-23.2% | Β· |
|
RARE
Ultragenyx Pharmaceutical
|
Oct 21, 2026 | BUY |
Strong Buy
+193.8% avg upside
36 analysts
|
$36.00
123.64% Upside
|
+4.9% | Β· |
|
TVTX
Travere Therapeutics
|
Oct 21, 2026 | BUY |
Strong Buy
+15.5% avg upside
22 analysts
|
$68.00
34.95% Upside
|
-2.8% | Β· |
|
RIGL
Rigel
|
Oct 21, 2026 | HOLD |
Strong Buy
-47.4% avg upside
17 analysts
|
$49.00
4.46% Downside
|
-12.2% | Β· |
|
IONS
Ionis Pharmaceuticals
|
Oct 21, 2026 | BUY |
Strong Buy
+74.1% avg upside
44 analysts
|
$87.00
99.87% Upside
|
-39.6% | Β· |
|
INCY
Incyte
|
Oct 21, 2026 | BUY |
Buy
-5.9% avg upside
49 analysts
|
$130.00
8.07% Upside
|
+5.5% | Β· |
|
CDXS
Codexis
|
Oct 21, 2026 | BUY |
Strong Buy
+746.4% avg upside
13 analysts
|
$8.00
572.35% Upside
|
-17.1% | Β· |
|
ENGN
enGene Holdings
|
Oct 16, 2026 | HOLD |
Buy
+553.6% avg upside
13 analysts
|
$4.00
161.38% Upside
|
+3.0% | Β· |
|
TYRA
Tyra Bioscience
|
Sep 08, 2026 | BUY |
Strong Buy
+107.4% avg upside
17 analysts
|
$56.00
165.71% Upside
|
-26.8% | Β· |
|
BHVN
Biohaven Ltd.
|
Aug 17, 2026 | BUY |
Buy
+51.3% avg upside
25 analysts
|
$30.00
94.51% Upside
|
-8.4% | Β· |
|
COGT
Cogent Biosciences
|
Aug 17, 2026 | BUY |
Strong Buy
+24.4% avg upside
26 analysts
|
$55.00
77.22% Upside
|
-26.5% | Β· |
|
HUMA
Humacyte
|
Aug 17, 2026 | HOLD |
Strong Buy
+1468.9% avg upside
11 analysts
|
$1.00
143.21% Upside
|
-10.7% | Β· |
|
ALXO
ALX Oncology Holdings
|
Aug 17, 2026 | BUY |
Strong Buy
+1370.8% avg upside
11 analysts
|
$4.00
227.79% Upside
|
-49.2% | Β· |
|
MGTX
Meiragtx Holdings
|
Aug 17, 2026 | BUY |
Strong Buy
+166.7% avg upside
14 analysts
|
$30.00
216.22% Upside
|
-38.6% | Β· |
|
IMRX
Immuneering
|
Aug 17, 2026 | BUY |
Strong Buy
+379.3% avg upside
12 analysts
|
$12.00
220.44% Upside
|
-35.4% | Β· |
|
REPL
Replimune Group
|
Aug 07, 2026 | BUY |
Strong Buy
+40.9% avg upside
14 analysts
|
$14.00
20.47% Downside
|
+63.3% | Β· |
|
ABCL
AbCellera Biologics
|
Aug 07, 2026 | BUY |
Strong Buy
+33.0% avg upside
18 analysts
|
$12.00
2.10% Downside
|
+59.2% | Β· |
|
IOBTQ
IO Biotech
|
Jan 23, 2026 | HOLD |
Buy
+4714900.0% avg upside
6 analysts
|
$0.50
499900.01% Upside
|
Β· | Β· |
|
ROIV
Roivant Sciences
|
Jul 18, 2024 | BUY |
Strong Buy
+10.7% avg upside
19 analysts
|
$22.00
40.39% Downside
|
+3.0% | Β· |
|
SLDB
Solid Biosciences
|
Mar 14, 2024 | BUY |
Strong Buy
+176.4% avg upside
26 analysts
|
$20.00
222.61% Upside
|
-58.6% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.